A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides - 17/08/13
Abstract |
Background |
Granulomatous mycosis fungoides (GMF) is an uncommon variant of mycosis fungoides (MF).
Objective |
We sought to analyze the relative frequency, clinicopathologic characteristics, prognosis, and therapeutic responses of GMF.
Methods |
We conducted a retrospective case-control study of patients with GMF and age- and stage-matched patients with classic MF between 1981 and 2012.
Results |
A total of 27 patients with GMF were identified, representing 6.3% of all patients with MF at our center. Skin manifestations were similar to classic MF having an atypical lichenoid CD4+ CD8− lymphocytic infiltrate with interstitial histiocytes and/or perivascular granulomas with giant cells. Fewer patients with GMF achieved a partial response or complete response with topical (57% vs 83%; P = .002) or ultraviolet light (62% vs 90%; P = .006) therapy. The 5- and 10-year progression-free survival rates were significantly lower in patients with GMF (59% and 33%) compared with patients with classic MF (84% and 56%; P = .02), but overall survival was similar between groups (86% and 72% vs 85% and 85%; P = .54).
Limitations |
The retrospective methodology may underestimate the frequency of GMF. The median follow-up time may be too short to detect possible differences in overall survival.
Conclusion |
More frequent disease progression and poorer response to skin-directed therapies were observed in patients with GMF. Our findings may be helpful in selecting the most appropriate treatment for these patients.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous T-cell lymphoma, disease progression, granulomatous mycosis fungoides, histopathology, incidence, outcome, treatment response
Abbreviations used : CR, EORTC, GMF, ISCL, LCT, MF, OS, PFS, PR, TCR, Th
Plan
| The first 2 authors contributed equally to this article. |
|
| Funding sources: None. |
|
| Disclosure: Dr Horwitz has received research grants from Celgene, Allos, Seattle Gen, Infinity Pharmaceuticals, and Kyowa Hakko Kirin. He has consulted for Celgene, Allos, Seattle Gen, Bristol-Myers Squibb, Genzyme, Kyowa Hakko Kirin Pharma, and Johnson & Johnson. Ms Li, and Drs Pulitzer, Myskowski, Dusza, Moskowitz, and Querfeld have no conflicts of interest to declare. |
Vol 69 - N° 3
P. 366 - septembre 2013 Retour au numéro
Article précédent
- Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients
- Octavio Servitje, Cristina Muniesa, Yolanda Benavente, Verónica Monsálvez, M. Pilar Garcia-Muret, Fernando Gallardo, Eva Domingo-Domenech, Anna Lucas, Fina Climent, Jose L. Rodriguez-Peralto, Pablo L. Ortiz-Romero, Juan Sandoval, Ramon M. Pujol, M. Teresa Estrach
- A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides
- Georgia Levidou, Marina Siakantaris, Theodora Papadaki, Evangelia Papadavid, Theodoros P. Vassilakopoulos, Maria K. Angelopoulou, Leonidas Marinos, Vassiliki Nikolaou, Aphroditi Economidi, Christina Antoniou, Efstratios Patsouris, Penelope Korkolopoulou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?